NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading MDGL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with a focus on growth. MDGL is currently in a mixed state, as it aims to improve its financial performance while expanding its market presence.
The market seems to have a low expectations gap, indicating that MDGL's current valuation reflects a durable premium compared to peers. This suggests that investors are not overly optimistic about immediate financial recovery.
Management is focused on driving growth for Rezdiffra, which has shown some progress in revenue growth. However, the company remains loss-making, and recent financial performance has been weak, indicating challenges ahead.
The long-term thesis hinges on MDGL's ability to maintain growth momentum for Rezdiffra and achieve financial stability. Additionally, the performance of sector bellwethers like VRTX, REGN, and ARGX will be crucial in shaping investor sentiment.
In the next 1-3 years, MDGL's performance will depend on its execution of growth strategies and external sector influences. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will show revenue, costs, and how well the company is doing.
Confirms one read:Earnings report shows revenue growth and improved net income.
Confirms the other:The earnings report shows falling revenue and bigger losses.
Why it matters: Sales growth below this level may mean less demand or more competition.
Confirms:Q2 Rezdiffra sales growth reported below 100% year over year.
Disproves:Q2 Rezdiffra sales growth reported at or above 100% year over year.
Why it matters: If healthcare sector growth speeds up, it could benefit Madrigal. A strong sector can lift individual stocks.
Confirms:Healthcare sector revenue growth exceeds 10% year over year.
Disproves:Healthcare sector revenue growth stays below 10% year over year.
Why it matters: Higher net income means the company is getting more stable. It also shows better cost control.
Confirms:Q2 net income improves to less than -$90M.
Disproves:Q2 net income worsens to more than -$100M.
Why it matters: New partnerships can boost growth and market reach for Rezdiffra.
Confirms:A new partnership was announced with a big healthcare company.
Disproves:No new partnerships announced in the next quarter.
Why it matters: Better financial stability helps the company grow. It also builds trust with investors.
Confirms:Net income improves to less than -$80M in Q2 2026.
Disproves:Net income worsens to more than -$100M in Q2 2026.
Why it matters: Good results could improve Madrigal's pipeline and help it in MASH.
Confirms:The ARO-PNPLA3 trial showed good results with a big drop in liver fat.
Disproves:Trial results show no significant reduction in liver fat.
Why it matters: A drop could raise worries about money and funding for growth.
Confirms:Cash reserves are below $800 million.
Disproves:Cash reserves remain at or above $800 million.
Why it matters: New partnerships could help Madrigal's pipeline and reach for MASH therapies.
Confirms:New partnerships announced to grow the pipeline.
Disproves:No new partnerships announced in Q2.
